Literature DB >> 7522396

Improvement of sickle cell anemia by iron-limited erythropoiesis.

O Castro1, W N Poillon, H Finke, E Massac.   

Abstract

We report the hematologic and clinical features of four adult patients (Pts.) with sickle cell anemia and iron-limited erythropoiesis. Two of the Pts. had spontaneous iron deficiency (chronic GI bleeding, low-grade hemoglobinuria). In the other two Pts. iron restriction was induced by periodic RBC aphereses as part of a pilot protocol designed to decrease intracellular HbS polymerization by MCHC reduction. Iron-limited erythropoiesis was defined by reduction in red cell indices (MCV range 60.4-67 fl) in the presence of low serum ferritin (range < 10-20 ng/ml). In these Pts. iron restriction did not cause clinically significant worsening of the anemia (Hb 7.8-9.0 g/dl). In two Pts. the anemia actually improved. Other hematologic effects of iron restriction were: decreased MCHC, reticulocyte count, RDW, and dense cells. A reduced hemolytic rate was suggested by a lowering of serum bilirubin and LDH. In one of the Pts. the 51Cr RBC T1/2 survival increased from 12 to 16 days. The intracellular HbS polymer fractions (fp) were determined at 25% O2 by Csat and with the use of the conservation of mass equation. The baseline fp values ranged from 0.48-0.53. After iron restriction they ranged from 0.33-0.48. The fp decreased even though iron-limited erythropoiesis also lowered the Hb F concentration in three of our Pts. In one of the two Pts. with induced iron depletion, hospitalization days for pain crises decreased from an average of 4.5 days/month (2 year baseline period) to an average of 0.5 days/month in the 3 year follow-up after iron depletion. The second patient with induced iron restriction experienced the rapid healing of a leg ulcer. Controlled iron restriction should be explored as a therapeutic strategy in selected SS patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7522396     DOI: 10.1002/ajh.2830470203

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

1.  Hemoglobin sickle cell disease complications: a clinical study of 179 cases.

Authors:  François Lionnet; Nadjib Hammoudi; Katia Stankovic Stojanovic; Virginie Avellino; Gilles Grateau; Robert Girot; Jean-Philippe Haymann
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

Review 3.  Treating sickle cell disease by targeting HbS polymerization.

Authors:  William A Eaton; H Franklin Bunn
Journal:  Blood       Date:  2017-04-06       Impact factor: 22.113

4.  Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches.

Authors:  Julia Zhe Xu; Swee Lay Thein
Journal:  Blood       Date:  2022-05-19       Impact factor: 25.476

5.  Sickle cell anemia: iron availability and nocturnal oximetry.

Authors:  Sharon E Cox; Veline L'Esperance; Julie Makani; Deogratius Soka; Andrew M Prentice; Catherine M Hill; Fenella J Kirkham
Journal:  J Clin Sleep Med       Date:  2012-10-15       Impact factor: 4.062

6.  Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease.

Authors:  Carly C Ginter Summarell; Vivien A Sheehan
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-17

Review 7.  Physiology and pathophysiology of iron in hemoglobin-associated diseases.

Authors:  Thomas D Coates
Journal:  Free Radic Biol Med       Date:  2014-04-12       Impact factor: 7.376

8.  Dietary iron restriction improves markers of disease severity in murine sickle cell anemia.

Authors:  Nermi L Parrow; Pierre-Christian Violet; Nisha Ajit George; Faris Ali; Shivam Bhanvadia; Ryan Wong; John F Tisdale; Courtney Fitzhugh; Mark Levine; Swee Lay Thein; Robert E Fleming
Journal:  Blood       Date:  2021-03-18       Impact factor: 25.476

Review 9.  Impact of hemoglobin biophysical studies on molecular pathogenesis and drug therapy for sickle cell disease.

Authors:  William A Eaton
Journal:  Mol Aspects Med       Date:  2021-07-14

10.  Hematological and Genetic Predictors of Daytime Hemoglobin Saturation in Tanzanian Children with and without Sickle Cell Anemia.

Authors:  Sharon E Cox; Julie Makani; Charles R Newton; Andrew M Prentice; Fenella J Kirkham
Journal:  ISRN Hematol       Date:  2013-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.